去泛素化酶在肿瘤发生中的作用

doi:10.3969/j.issn.1004-616x.2015.06.017

癌变·畸变·突变 ›› 2015, Vol. 27 ›› Issue (6): 484-486.doi: 10.3969/j.issn.1004-616x.2015.06.017

去泛素化酶在肿瘤发生中的作用

张敬洋, 陈晓煜, 胡涛, 马扬程, 高纯志, 张奕琳, 杨胜利, 李沛, 陈平, 董子明

郑州大学基础医学院, 河南省化学预防协同创新中心, 河南郑州 450001

收稿日期:2015-07-21 修回日期:2015-10-12 出版日期:2015-11-30 发布日期:2015-11-30
通讯作者: 陈平,E-mail:zzdx_chenping@zzu.edu.cn E-mail:zzdx_chenping@zzu.edu.cn
作者简介:张敬洋,E-mail:18236966956@163.com。
基金资助:
国家自然科学基金(81001102,81101894);高校新世纪优秀人才计划(NCET-11-0949);河南省高等学校重点科研项目计划(15A310024)

Received:2015-07-21 Revised:2015-10-12 Online:2015-11-30 Published:2015-11-30

摘要/Abstract

摘要： 泛素-蛋白酶体系统是细胞内非常重要的蛋白质降解调节系统。蛋白质泛素化和去泛素化调节的动态平衡,影响或者调节细胞的生长发育、信号转导、神经病变或者肿瘤等许多细胞生理病理过程。目前研究证实,细胞内广泛存在多种去泛素化酶,通过选择性地降解或稳定癌基因、抑癌基因以及其他与细胞生物学相关的底物蛋白,与肿瘤的发生、发展密切相关。本文对去泛素化酶的分类、结构、作用机制、活性调节及其在肿瘤发生中的作用作一综述,拟为研究肿瘤的发生、发展提供新的理论依据,并有助于我们开发以及应用针对去泛素化酶的分子靶向药物。

关键词: 去泛素化酶, 蛋白质降解, 肿瘤发生, 分子靶向药物

中图分类号:

R730.2

张敬洋, 陈晓煜, 胡涛, 马扬程, 高纯志, 张奕琳, 杨胜利, 李沛, 陈平, 董子明. 去泛素化酶在肿瘤发生中的作用[J]. 癌变·畸变·突变, 2015, 27(6): 484-486.

参考文献

[1] D'Arcy P,Linder S. Molecular pathways:translational potential of deubiquitinases as drug targets[J]. Clin Cancer Res,2014,20(15):3908-3914.
[2] Ernst A,Avvakumov G,Tong J,et al. A strategy for modulation of enzymes in the ubiquitin system[J]. Science,2013,339(6119):590-595.
[3] Komander D,Clague MJ,Urbe S. Breaking the chains:structure and function of the deubiquitinases[J]. Nat Rev Mol Cell Biol,2009, 10(8):550-563.
[4] D'Arcy P,Wang X,Linder S. Deubiquitinase inhibition as a cancer therapeutic strategy[J]. Pharmacol Ther,2015,147:32-54.
[5] D'Arcy P,Brnjic S,Olofsson MH,et al. Inhibition of proteasome deubiquitinating activity as a new cancer therapy[J]. Nat Med,2011, 17(12):1636-1640.
[6] Jiao L,Ouyang S,Shaw N,et al. Mechanism of the Rpn13-induced activation of Uch37[J]. Protein & Cell,2014,5(8):616-630.
[7] Stevenson LF,Sparks A,Allende-Vega N,et al. The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2[J]. EMBO J,2007,26(4):976-986.
[8] Zhang X,Berger FG,Yang J,et al. USP4 inhibits p53 through deubiquitinating and stabilizing ARF-BP1[J]. EMBO J,2011, 30(11):2177-2189.
[9] Khoronenkova SV,Dianova,II,Ternette N,et al. ATM-dependent downregulation of USP7/HAUSP by PPM1G activates p53 response to DNA damage[J]. Mol Cell,2012,45(6):801-813.
[10] Liu Z,Zanata SM,Kim J,et al. The ubiquitin-specific protease USP2a prevents endocytosis-mediated EGFR degradation[J]. Oncogene, 2013,32(13):1660-1669.
[11] De A,Dainichi T,Rathinam CV,et al. The deubiquitinase activity of A20 is dispensable for NF-kappaB signaling[J]. EMBO Rep,2014, 15(7):775-783.
[12] Eichhorn PJ,Rodon L,Gonzalez-Junca A,et al. USP15 stabilizes TGF-beta receptor I and promotes oncogenesis through the activation of TGF-beta signaling in glioblastoma[J]. Nat Med,2012,18(3):429-435.
[13] Lui TT,Lacroix C,Ahmed SM,et al. The ubiquitin-specific protease USP34 regulates axin stability and Wnt/beta-catenin signaling[J]. Mol Cell Biol,2011,31(10):2053-2065.
[14] Diaz-Moralli S,Tarrado-Castellarnau M,Miranda A,et al. Targeting cell cycle regulation in cancer therapy[J]. Pharmacol Ther,2013, 138(2):255-271.
[15] Shi Y,Solomon LR,Pereda-Lopez A,et al. Ubiquitin-specific cysteine protease 2a(USP2a) regulates the stability of Aurora-A[J]. J Biol Chem,2011,286(45):38960-38968.
[16] Lin Z,Yang H,Kong Q,et al. USP22 antagonizes p53 transcriptional activation by deubiquitinating Sirt1 to suppress cell apoptosis and is required for mouse embryonic development[J]. Mol Cell,2012,46(4):484-494.
[17] Graner E,Tang D,Rossi S,et al. The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer[J]. Cancer Cell, 2004,5(3):253-261.
[18] Liu J,Xia H,Kim M,et al. Beclin1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13[J]. Cell,2011,147(1):223-234.
[19] Taillebourg E,Gregoire I,Viargues P,et al. The deubiquitinating enzyme USP36 controls selective autophagy activation by ubiquitinated proteins[J]. Autophagy,2012,8(5):767-779.
[20] Cao J,Yan Q. Histone ubiquitination and deubiquitination in transcription,DNA damage response,and cancer[J]. Front Oncol, 2012,2:26.
[21] Al-Hakim A,Escribano-Diaz C,Landry MC,et al. The ubiquitous role of ubiquitin in the DNA damage response[J]. DNA Repair(Amst),2010,9(12):1229-1240.
[22] Zhang XY,Pfeiffer HK,Thorne AW,et al. USP22,an hSAGA subunit and potential cancer stem cell marker,reverses the polycombcatalyzed ubiquitylation of histone H2A[J]. Cell Cycle,2008,7(11):1522-1524.
[23] Joo HY,Jones A,Yang C,et al. Regulation of Histone H2A and H2B Deubiquitination and Xenopus Development by USP12 and USP46[J]. J Biol Chem,2010,286(9):7190-7201.
[24] Zhang Y,Zhou X,Huang P. Fanconi Anemia and Ubiquitination[J]. J Genet Genom,2007,34(7):573-580.
[25] Clague MJ,Coulson JM,Urbe S. Deciphering histone 2A deubiquitination[J]. Genome Biol,2008,9(1):202.
[26] Mosbech A,Lukas C,Bekker-Jensen S,et al. The deubiquitylating enzyme USP44 counteracts the DNA double-strand break response mediated by the RNF8 and RNF168 ubiquitin ligases[J]. J Biol Chem,2013,288(23):16579-16587.
[27] Yao T,Song L,Jin J,et al. Distinct modes of regulation of the Uch37 deubiquitinating enzyme in the proteasome and in the Ino80 chromatinremodeling complex[J]. Mol Cell,2008,31(6):909-917.
[28] Tung JC,Barnes JM,Desai SR,et al. Tumor mechanics and metabolic dysfunction[J]. Free RadBiol& Med,2015,79:269-280.
[29] Kim SR,Kim JO,Lim KH,et al. Regulation of pyruvate kinase isozyme M2 is mediated by the ubiquitin-specific protease 20[J]. Int J Oncol,2015,46(5):2116-2124.

去泛素化酶在肿瘤发生中的作用

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 5

编辑推荐

Metrics

本文评价

[1]	张春雷, 杨琦, 訾晓渊, 孙颖浩. 环状RNA在肿瘤中作用的研究进展[J]. 癌变·畸变·突变, 2020, 32(6): 477-480,484.
[2]	曹文波,莫赛军,柯少瑞,张宏波,杨胜利. 钙结合蛋白S100A8和S100A9在慢性炎症相关肿瘤发生中的调控作用[J]. 癌变·畸变·突变, 2013, 25(5): 403-406.
[3]	胡元庆1(综述);张宏权2(审校). 丝氨酸/苏氨酸蛋白激酶4生物学特性的研究进展[J]. , 2010, 22(1): 75-0077.
[4]	王钰婷，薛立辉(综述)，聂刘旺(审校). SOX基因与肿瘤关系的研究进展[J]. , 2009, 21(1): 77-.
[5]	许铭炎,邓小玲　综述,徐小虎,黄天华　审校. DNA 错配修复基因与肿瘤研究新进展[J]. , 2002, 14(4): 256-260.